ArticleJAAD case reports2021
Semaglutide-associated bullous pemphigoid.
Article in JAAD case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Glucagon-like peptide-1-based therapies and the intersection of metabolic and skin disease.JAAD case reports · 2026Article
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.Dermatology and therapy · 2025Review
- Granuloma annulare after starting semaglutide.JAAD case reports · 2025Article
- GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review.Advances in therapy · 2025Review
- A Closer Look at the Dermatological Profile of GLP-1 Agonists.Diseases (Basel, Switzerland) · 2025Review
- A Review of Glucagon-like Peptide-1 in Dermatology.The Journal of clinical and aesthetic dermatology · 2025Review
- The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.Medicina (Kaunas, Lithuania) · 2024Review
- Acute generalized exanthematous pustulosis sine pustules following semaglutide injection.JAAD case reports · 2024Article
- Skin-Related Adverse Reactions Induced by Oral Antidiabetic Drugs-A Review of Literature and Case Reports.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.Dermatology reports · 2023Article
- Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature.Clinical rheumatology · 2023Review
- Treatment of Diabetes in Bullous Pemphigoid Patients: Where Do We Stand?Dermatology practical & conceptual · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.